---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-052718"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:14:11.104516+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Roivant reports Q2 net loss $331M; announces $7.1B Telavant sale to Roche

## Summary
- Net loss $331.1M ($0.40/share) vs $315.9M prior year; revenue $37.1M up from $12.5M.
- Sold Telavant to Roche for $7.1B upfront + $150M milestone; Roivant net proceeds ~$5.2B.
- VTAMA net product revenue $18.4M in quarter; over 250k prescriptions since launch.
- Pro forma cash ~$7.0B after Telavant and Immunovant offerings; R&D spend $132M.
- IMVT-1402 Phase 1 data show dose-dependent IgG reduction with no significant albumin/LDL-C changes.

## SEC filing metadata
- accession: 0001140361-23-052718
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/ef20014462_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-052718
- JSON: https://secwatch.observer/filing/0001140361-23-052718.json
- Plain text: https://secwatch.observer/filing/0001140361-23-052718.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for the second quarter ended September 30, 2023.
  - Period: the second quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.